Skip to main content

Table 2 Comparison of tumors from different patient groups based on frequencies of hypermethylation at miRNA loci

From: Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma

  Proportion of tumors with hypermethylation a
Tumor category 572 129-2 663 375-I 345 132 34a
MSI vs. MSS
Sporadic Finnish MSI-CRC (n = 40) vs. sporadic Finnish MSS-CRC (n = 47) 13/40 vs. 13/47 37/40 vs. 34/47 28/40 vs. 28/47 0/40 vs. 1/47 24/40 vs. 13/47* 23/40 vs. 1/47*** 23/40 vs. 20/47
Sporadic Australian MSI-CRC (n = 38) vs. sporadic Australian MSS-CRC (n = 52) 9/38 vs. 9/52 28/38 vs. 42/52 30/38 vs. 44/52 10/38 vs. 14/52 13/38 vs. 5/52* 15/38 vs. 6/52* 10/38 vs. 15/52
Sporadic vs. hereditary        
Sporadic Finnish MSI-CRC (n = 40) vs. Finnish Lynch-CRC (n = 28) 13/40 vs. 12/28 37/40 vs. 23/28 28/40 vs. 18/28 0/40 vs. 8/28** 24/40 vs. 12/28 23/40 vs. 2/28*** 23/40 vs. 13/28
Colorectal vs. endometrial        
Finnish Lynch-CRC (n = 28) vs. Finnish Lynch-EC (n = 36) 12/28 vs. 16/36 23/28 vs. 16/36* 18/28 vs. 22/36 8/28 vs. 5/36 12/28 vs. 3/36* 2/28 vs. 11/36 13/28 vs. 20/36
Finnish vs. Australian        
Sporadic Finnish MSI-CRC (n = 40) vs. sporadic Australian MSI-CRC (n = 52) 13/40 vs. 9/38 37/40 vs. 28/38 28/40 vs. 30/38 0/40 vs. 10/38** 24/40 vs. 13/38 23/40 vs. 15/38 23/40 vs. 10/38*
Sporadic Finnish MSS-CRC (n = 47) vs. sporadic Australian MSS-CRC (n = 52) 13/47 vs. 9/52 34/47 vs. 42/52 28/47 vs. 44/52* 1/47 vs. 14/52** 13/47 vs. 5/52 1/47 vs. 6/52 20/47 vs. 15/52
  1. aUsing cutoffs determined by methylation in the respective normal tissues (Additional file 8: Table S5). P values determined by Fisher’s exact test and adjusted for multiple testing are shown after each comparison, (* P < 0.05; ** P < 0.01; *** P < 0.001). All tumors were informative for all markers.